This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 524 studies, archived under the term: "alzheimer disease"

Click here to filter this large number of results.

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Background: Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer’s disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients.; Methods: We did a multicentre, placebo-controlled phase 2 trial at seven sites in the USA and five in Germany. Participants with probable Alzheimer’s […]

Effect of a non-pharmacological intervention, Voix d’Or(®), on behavior disturbances in Alzheimer disease and associated disorders

An innovative non-pharmacological intervention called Voix d’Or(®) (Golden Voice) was proposed in the Cognitive behavioral unit (CBU) of the Memory center at the Hospices civils in Lyon. Voix d’Or(®) offers eight sound activities disseminated via an audio device based on different approaches sociotherapeutic (music therapy, reminiscence, relaxation, reorientation in reality). The aim of this study […]

Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study

This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer’s disease (AD) patients. Thirty mild-moderate AD patients on cholinesterase inhibitor treatment were administered escalating doses (400, 600, 800, 1,000 mg) of tideglusib or placebo (ratio 2 : 1) for 4, 4, 6, […]

The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer’s disease: a randomised controlled study

Background: Synaptic loss is a major hallmark of Alzheimer’s disease (AD). Disturbed organisation of large-scale functional brain networks in AD might reflect synaptic loss and disrupted neuronal communication. The medical food Souvenaid, containing the specific nutrient combination Fortasyn Connect, is designed to enhance synapse formation and function and has been shown to improve memory performance […]

Do patients diagnosed with Alzheimer’s disease benefit from a psycho-educational programme for family caregivers? A randomised controlled study

Objective: The Aide dans la Maladie d’Alzheimer (AIDMA) study was conducted to determine whether a psycho-educational programme (PEP) for primary caregivers in addition to standard anti-dementia drugs for patients improves caregivers’ psychological condition and patients’ activities of daily life.; Method: Multicentre randomised controlled intervention trial. One hundred and sixty-seven dyads ‘patient-caregiver’ were recruited from 15 […]

Silicon-rich mineral water as a non-invasive test of the ‘aluminum hypothesis’ in Alzheimer’s disease

There has been a plausible link between human exposure to aluminum and Alzheimer’s disease for several decades. We contend that the only direct and ethically acceptable experimental test of the ‘aluminum hypothesis’, which would provide unequivocal data specific to the link, is to test the null hypothesis that a reduction in the body burden of […]

Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors

Despite three decades of intensive research in the field of Alzheimer’s disease (AD) and numerous clinical trials of new therapeutic agents, cholinesterase inhibitors (ChEIs) are still the mainstay of therapeutics for AD and dementia with Lewy bodies. Pharmacodynamic analyses of ChEIs provide paradoxical observations. Treatment with the rapidly reversible, noncarbamylating ChEIs (donepezil, galantamine, and tacrine) […]

Neuromidin in mixed vascular and Alzheimer’s dementia

The efficacy of neuromidin (ipidacrinum), a nonselective inhibitor of acetylcholinesterase and butyrilcholinesterase was studied in patients with mixed vascular and Alzheimer’s dementia of mild and moderate severity. Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of […]

A videophone psychosocial intervention for dementia caregivers

Background/objectives: Available services and intervention programs for dementia caregivers are often underutilized because of issues such as cost, logistics, lack of knowledge about available services, or insufficient support from others. Information technologies offer the potential of removing these barriers and facilitating the ability of caregivers to access needed support. This project evaluated the feasibility and […]

Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer’s disease: a 12-month, randomized, open-label trial

Background: Behavioral and psychological symptoms of dementia (BPSD) occur in up to 80% of Alzheimer’s disease (AD) patients and represent one of the most common reasons for early institutionalization and increase in management costs.; Objectives: This study evaluated the effects of four drugs (memantine, donepezil, rivastigmine, galantamine) in BPSD in AD patients.; Methods: This was […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below: